OncoMatch/Clinical Trials/NCT07159620
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Official title: A Prospective Single-Arm Clinical Study of Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Is NCT07159620 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments for adult t-cell leukemia/lymphoma.
Treatment: VEN (Venetoclax) · Azacitidine (AZA) · Chidamide · vindesine · Dexamethasone — ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: ASXL1 mutation
Required: ASXL2 mutation
Required: BCOR mutation
Required: BCORL1 mutation
Required: DNMT3A mutation
Required: EZH2 mutation
Required: FLT3 mutation
Required: IDH1 mutation
Required: IDH2 mutation
Required: RUNX1 mutation
Required: SF3B1 mutation
Required: STAG2 mutation
Required: TET2 mutation
Required: WT1 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
Serum creatinine <2 mg/dL, creatinine clearance >30 mL/min/1.73m²
Liver function
Total bilirubin <2x ULN, ALT/AST <3x ULN
Cardiac function
LVEF >40%, no history of congestive heart failure, unstable coronary artery disease, or severe arrhythmia
Severe Organ Dysfunction: Cardiac Insufficiency: LVEF ≤40%, OR history of congestive heart failure, unstable coronary artery disease, or severe arrhythmia. Hepatic Impairment: Total bilirubin ≥2x ULN, ALT or AST ≥3x ULN. Renal Impairment: Serum creatinine ≥2 mg/dL, OR creatinine clearance ≤30 mL/min/1.73m².
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07159620 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ASXL1?
Yes, ASXL1 mutation is a required biomarker for enrollment.
Does this trial require ASXL2?
Yes, ASXL2 mutation is a required biomarker for enrollment.
Does this trial require BCOR?
Yes, BCOR mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify